Filter news by year:
Sept 13, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announced that a patent application has been filed with the U.S. Patent Office. If the application is subsequently granted, QuiaPEG will obtain a patent protection to at least the end of 2038.

Sept 03, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that the company's CEO, Marcus Bosson, has on 31/8 and 3/9 in total acquired 100,000 shares at an average price of SEK 2.02 and that on 3 September, Board member Anders Vedin has acquired 99,806 shares at an average price of SEK 2.14.

Aug 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) receives "Notice of Allowance" regarding granting of a patent in the United States.

July 22, 2018

At the board meeting of the company held on April 26, 2018 the board of directors of QuiaPEG resolved, based on its authorization, to issue 6 000 000 warrants without consideration to the Dutch investment group, Nyenburgh Holding B.V. Each warrants provides entitlement to subscription of 1 new share in QuiaPEG with a quotient value of SEK 0.9, which means that the share capital can increase by a maximum of SEK 5 400 000 upon full exercise of the warrants through subscription of a maximum of 6 000 000 new shares. The warrants may be exercised for subscription of shares in the Company during the period from and including the day of issue of the warrants up to and including April 30, 2021. The subscription rate per share shall amount to SEK 3,50. The issue of the warrants is now registered.

QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message